GlobalData on MSN1d
Sanofi reports Q4 2024 increase in net income to $916m
Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...
Sanofi: Positioned for Strong Growth with Conservative Guidance and Strategic Initiatives
Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to ...
Sanofi’s Strong Growth Prospects and Strategic Initiatives Justify Buy Rating
Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...
Sanofi targets mid to high single-digit sales growth in 2025 with €5B share buyback plan
Q4 2024 Management View Paul Hudson highlighted significant progress in 2024 towards becoming a focused science-driven ...
Zacks.com on MSN2d
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
Sanofi SNY reported fourth-quarter 2024 adjusted earnings of 70 cents per American depositary share, which missed the Zacks Consensus Estimate of 71 cents per share. Earnings of €1.31 per share ...
BioSpace2d
Sanofi Earnings Driven by Dupixent, New RSV Vaccine as Hunt for Deals Continues
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
Sanofi Expected to Report Lower Sales, Profit; Size of Buyback in Focus -- Earnings Preview
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...
Sanofi Q4 Earnings Miss, 2025 Outlook Impresses
SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.